Arcutis Biotherapeutics, Inc. (ARQT) SEC Filings & Earnings Calls

Single-source supplier dependency

“Many of these suppliers that we rely on are single-source suppliers.” · word for word

Terminated promotion agreement

“Effective January 23, 2026, we mutually agreed to terminate the promotion agreement.” · word for word

Accumulated deficit

“As of June 30, 2026, we had an accumulated deficit of $1,134.4 million” · word for word

Dependence on ZORYVE franchise for revenue; pipeline and regulatory risks.

“Revenue is concentrated in ZORYVE products; pipeline includes Phase 2 trials with uncertain outcomes.”

Terminated Kowa promotion agreement may impact primary care reach

“Effective January 23, 2026, we mutually agreed to terminate the promotion agreement. Following this termination, Kowa ceased all sales and promotions of ZORYVE” · word for word

Single-source supplier dependency for manufacturing

“Many of these suppliers that we rely on are single-source suppliers.” · word for word

Accumulated deficit and history of losses

“We have incurred annual net losses in each year since inception, including net losses of $11.3 million and $25.1 million for the three months ended March 31, 2026 and 2025, respectively.” · word for word

Dependence on ZORYVE for revenue; pipeline and regulatory risks.

“Pipeline includes Phase 2 studies for vitiligo and hidradenitis suppurativa; sNDA pending for plaque psoriasis.”

Commercialization dependence on ZORYVE

“Our business is dependent on the successful commercialization of ZORYVE and the development, regulatory approval, and commercialization of our product candidates.” · word for word

Going concern risk / need for additional financing

“We have incurred significant losses since our inception, and could continue to incur losses, which, together with our limited history as a commercial-stage company, makes it difficult to assess our future viability.” · word for word

Kowa agreement termination

“Effective January 23, 2026, we mutually agreed to terminate the promotion agreement. Following this termination, Kowa ceased all sales and promotions of ZORYVE and we will not be required to make any further payments to Kowa.” · word for word

Loss of founder from board; mitigated by consulting role.

“Director has resigned and shall cease to be a member of the Board” · word for word

Dependence on ZORYVE franchise for revenue; pipeline still early stage.

“ZORYVE is the only commercial product; pipeline includes early-stage programs.”

Dependence on single product family

“We have no internal manufacturing capabilities and we rely on third parties, many of whom are single source suppliers, for our nonclinical and clinical trial materials, as well as the commercial supply of our products.” · word for word

Debt covenant compliance

“We also agreed to a financial covenant whereby we must generate a minimum net product revenue equal to 75% of our projected net product revenue as set forth in our annual plan for the respective period, tested on a trailing six-month basis as of the end of each month.” · word for word

Limited pipeline diversification

“Following the completion of a Phase 1b study in the middle of 2025, we elected to halt further development of the program.” · word for word